{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
electroCore, Inc. Hits New 52-Week High of $10.35, Reflecting Strong Growth
electroCore, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low and demonstrating strong performance over the past year. With a market capitalization of USD 50 million, the company has shown impressive return on equity despite being unprofitable and not offering dividends.
electroCore, Inc. Hits New 52-Week High of $10.27, Reflecting Strong Growth
electroCore, Inc. has achieved a new 52-week high, reflecting a significant performance improvement over the past year. With a market capitalization of USD 50 million, the company has shown remarkable return on equity despite being loss-making. Its unique valuation and recent momentum highlight its competitive position in the pharmaceuticals and biotechnology sector.
electroCore, Inc. Hits New 52-Week High of $9.64, Reflecting Strong Growth
electroCore, Inc. has achieved a new 52-week high, reflecting a strong performance over the past year with a significant stock increase. The company, classified as a microcap, has a market capitalization of USD 50 million and showcases a remarkable return on equity despite being unprofitable.
electroCore, Inc. Hits New 52-Week High of $9.18, Surpassing Previous Milestones
electroCore, Inc. has achieved a new 52-week high, reflecting a strong one-year performance that surpasses the S&P 500. Despite being unprofitable, the company boasts an impressive return on equity and operates in a competitive biotechnology sector, with notable financial metrics indicating a leveraged position and valuation considerations.
Is electroCore, Inc. technically bullish or bearish?
As of September 12, 2025, electroCore, Inc. is in a bearish trend, indicated by negative signals from daily moving averages, monthly MACD, and Bollinger Bands, with a year-to-date return of -69.19% compared to the S&P 500's 12.22%.
Is electroCore, Inc. overvalued or undervalued?
As of May 14, 2019, electroCore, Inc. is considered risky and overvalued due to a high Price to Book Value of 9.74, negative EV to EBIT and EV to EBITDA ratios, and a significantly negative Return on Equity of -280.30%, while its stock has underperformed the S&P 500 with a year-to-date return of -69.19%.
Is electroCore, Inc. overvalued or undervalued?
As of May 14, 2019, electroCore, Inc. is considered risky and overvalued due to negative earnings metrics, a high price-to-book ratio of 9.74, an EV to EBITDA ratio of -3.20, and a staggering ROE of -280.30%, with a year-to-date stock performance of -68.35%, significantly underperforming the S&P 500.
Is electroCore, Inc. technically bullish or bearish?
As of June 18, 2025, electroCore, Inc. shows a mildly bearish trend, with bearish indicators from MACD, moving averages, and Bollinger Bands, despite mixed signals from the KST.
Who are in the management team of electroCore, Inc.?
As of March 2022, the management team of electroCore, Inc. includes Independent Chairman Mr. Michael Atieh, CEO and Director Mr. Daniel Goldberger, Directors Mr. Joseph Errico, Mr. Peter Cuneo, Dr. Thomas Errico, Mr. John Gandolfo, and Mr. Trevor Moody. They oversee the company's strategic direction and operations.
What does electroCore, Inc. do?
ElectroCore, Inc. is a bioelectronic medicine company focused on developing non-invasive vagus nerve stimulation (nVNS) therapy for various medical conditions. As of March 2025, it reported net sales of $7 million and a net loss of $4 million, with a market capitalization of $37.70 million.
How big is electroCore, Inc.?
As of Jun 18, electroCore, Inc. has a market capitalization of 37.70 million, with net sales of 26.46 million and a net profit of -12.23 million over the latest four quarters. The company reported shareholder's funds of 7.54 million and total assets of 21.62 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
